{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "DSGN",
  "name": "Design Therapeutics, Inc.",
  "url": "https://orbyd.app/dossiers/DSGN/",
  "json_url": "https://orbyd.app/dossiers/DSGN.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "The June–July re-rate has run into an empty calendar. The 2026-08-03 Q2 update pushed DT-168 FECD data to 2027 and re-cut RESTORE-FA to a 10-patient 12-week cohort with blood FXN protein as the primary efficacy endpoint, moving the next hard data to Q1 2027. Tape is momentum-extended (RSI 77.3 at $13.99, 2026-08-07) with the Q4-2026 registrational update as the next real binary.",
  "invalidation_trigger": "A weekly close below $13.50 breaks the shelf that carried the June–July reclaim and returns the name to post-print broken structure; secondarily, the Q4-2026 registrational-plans update coming and going without a defined path on the blood FXN protein primary endpoint.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "rare-disease-gene-therapy",
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Clinical-stage and pre-revenue: all value sits in DT-216P2, DT-168 and DT-818 readouts, with no product sales to cushion a data miss.",
    "Weighted-average shares outstanding 62.5M (Q2 2026) — a thin float in which a single dated headline moves the quote violently both ways.",
    "RESTORE-FA's primary efficacy endpoint is now blood FXN protein percent change from baseline (2026-08-03), no longer a clinical scale such as mFARS.",
    "Cash and investments $207.4M at 2026-06-30; runway was guided into 2029 at the Q1 2026 report, so a raise is optional rather than forced.",
    "Friedreich ataxia competitive set: approved Skyclarys/omaveloxolone (Biogen/Reata), Larimar (LRMR) nomlabofusp, PTC Therapeutics (PTCT) vatiquinone.",
    "Pipeline readouts now cluster in 2027 (RESTORE-FA 12-week Q1-2027; DT-168 and DT-818 in 2027), leaving a long stretch with no scheduled data."
  ],
  "body_markdown": "## Current Thesis\nThe narrative leg an investor is buying here is platform validation: GeneTAC small molecules restoring endogenous frataxin in Friedreich ataxia, with the same chemistry aimed at FECD (DT-168) and myotonic dystrophy type 1 (DT-818). That leg re-rated the stock +40.22% in June and back to $15.19 (2026-07-10) after the 2026-05-18 RESTORE-FA topline closed -25.5% at $10.22.\n\nThe 2026-08-03 Q2 update changed the shape of the trade rather than the story. Management is modifying RESTORE-FA to a 1 mpk go-forward dose, a 10-patient 12-week cohort, and a primary efficacy endpoint of endogenous blood FXN protein percent change from baseline, with 12-week topline in Q1 2027 and a registrational-plans update in Q4 2026. In the same release, DT-168 Phase 2 biomarker data slipped from 2H-2026 to 2027 on manufacturing supply issues with the eye-dropper formulation. The nearest dated data binary the prior frame leaned on has therefore moved out roughly a year.\n\nThe tape took it well — +4.76% on the update day and +9.6% month-to-date through 2026-08-07 — which is what leaves the setup awkward: RSI(14) 77.3 at a $13.99 close that still sits 11.4% under the $15.79 52-week high (adjusted basis), with nothing company-dated inside 30 days.\n\n**Life-cycle: MATURING.** The theme flipped to accelerating on 2026-07-12 and the name is still working (+53.7% YTD, +252.4% over 52 weeks per StockTitan, 2026-08-07). What has moderated is the headline supply: after 2026-08-03 there is no scheduled clinical readout until Q1 2027. Well known inside the FA pool, still bid, thinner catalyst flow.\n\n## Bull Case\n- 2026-05-18 RESTORE-FA four-week IV data at 1 mpk: whole-blood FXN mRNA +65%, FXN-M/FXN-E protein +22–27%, muscle FXN mRNA +42%, mean mFARS +6.4 points and PROMIS Fatigue improvement >5 points versus a 3-point minimal-important-change bar.\n- Endpoint re-cut is executable: a 10-patient, 12-week cohort with blood FXN protein as primary (2026-08-03) reads out faster and on the measure the four-week data already moved, rather than on a clinical scale that needs duration and blinding.\n- Pipeline breadth intact: DT-818 Phase 1 MAD dosing in DM1 patients initiated 2026-06-30, data 2027; DT-168 Phase 2 in FECD ongoing, data 2027.\n- Balance sheet does not force a raise into a readout: cash, equivalents and investment securities $207.4M at 2026-06-30, against a Q2 net loss of $20.2M (R&D $16.4M, G&A $5.8M).\n- Sell-side is uniformly positive on rating: 6 analysts, Strong Buy consensus (MarketBeat, retrieved 2026-08-08); Q2 EPS -$0.32 beat the -$0.34 estimate (2026-08-03).\n\n## Bear Case\n- The nearest dated binary vanished on 2026-08-03: DT-168 FECD biomarker data moved from 2H-2026 to 2027, and the cause was manufacturing supply of an eye-dropper formulation — an execution problem, not a data problem, but it re-prices the option value of the second asset.\n- Switching the RESTORE-FA primary efficacy endpoint from clinical measures to blood FXN protein percent change (2026-08-03) means the Q1-2027 readout, even if clean, does not settle whether frataxin restoration translates into function.\n- Statistical power stays thin: 10 patients, 12 weeks, in a slowly progressive degenerative disease. The -25.5% reaction to the four-week data (2026-05-18) showed the market already discounts small open-label cohorts.\n- Safety flag carried forward: transient ALT elevations in three patients, all on background omaveloxolone (2026-05-18), with dose and duration both scaling in the modified cohort.\n- Cash and investments were $207.4M at 2026-06-30 versus $222.8M at 2026-03-31; runway was guided into 2029 at the Q1 2026 report, which makes an opportunistic raise near the high end of the range available rather than necessary.\n- Sell-side targets no longer imply much headroom on one measure: Investing.com shows a 6-analyst average 12-month target of $14.67 with a $12 low and $18 high (retrieved 2026-08-08) against a $13.99 close; MarketBeat's consensus target is $16.50 on the same date. The dispersion itself is the datapoint.\n- Crowded indication: approved Skyclarys/omaveloxolone (Biogen/Reata), Larimar (LRMR) nomlabofusp and PTC (PTCT) vatiquinone all address the same frataxin-deficiency pool.\n\n## Setup & Price Structure\nLast completed daily close $13.99 (2026-08-07). RSI(14) 77.3. Distance from the $15.79 52-week high: -11.4%. Three-month return -1.6% — a full round trip through the 2026-05-18 gap-and-fade.\n\nThree levels frame it. $14.37 is the 2026-05-18 data-day high, reclaimed on the June–July rally and now overhead again on a closing basis. $13.50 is the shelf underneath that reclaim; it has not been given back on a weekly close. $10.22 (2026-05-18 close) is the post-print low reference the June base was built on.\n\nPositioning observables, stated without a verdict: RSI 77.3 while price is still 11.4% below the 52-week high — momentum extended inside the July range rather than through it; +9.6% month-to-date through 2026-08-07 after a +4.76% session on the Q2 update; weighted-average shares outstanding 62.5M in Q2 2026, a small float in which single headlines move the quote hard; the Q2 print is behind (2026-08-03), so there is no earnings date inside the next 30 days; no offering, shelf takedown or insider sale is visible in the filings available as of 2026-08-08 — absence of evidence, and worth re-checking on any strength toward the 52-week high.\n\n## Catalyst Calendar (next 30 days)\n- **Through ~2026-09-07: no company-dated event.** The Q2 report and RESTORE-FA development update landed 2026-08-03; nothing scheduled replaces it inside the window.\n- **~2026-09-08 (est.), September healthcare-conference season** — H.C. Wainwright and other early-September investor conferences typically fall here; no DSGN participation was announced as of 2026-08-08. Only relevant if a presentation adds detail on the modified RESTORE-FA protocol.\n- **Q4 2026 (company-guided window)** — registrational-plans update for DT-216P2. The first event that can define what a filing package looks like on a biomarker primary endpoint.\n- **~2026-11-05 (est.)** — Q3 2026 results and business update; the checkpoint for whether the Q1-2027 12-week timeline holds.\n- **Q1 2027 (company-guided)** — RESTORE-FA 12-week topline from the 10-patient 1 mpk cohort. The next hard data binary.\n\n## What Would Change Our Mind\nThe structure that matters is the June–July reclaim of the 2026-05-18 data-day high at $14.37, and its floor. Losing that floor on a weekly close below $13.50 would put the name back into the post-print broken pattern the June base repaired, and would say the market is re-discounting the endpoint change rather than crediting it.\n\nThree non-price conditions would do the same work. First, the Q4-2026 registrational-plans update arriving without a defined path — no stated endpoint agreement, no cohort size, no filing framework — after which the story has no dated event before Q1 2027. Second, any further slip of the Q1-2027 12-week readout at the ~2026-11-05 Q3 update; the DT-168 delay (2026-08-03) established that manufacturing can move timelines a year. Third, an equity raise priced into strength while the calendar is empty, which would reset the share count ahead of the readout that is supposed to re-rate it.\n\nOn the other side, evidence that would extend the frame rather than break it: a Q4-2026 update specifying an agreed registrational endpoint, or an unscheduled DT-168 manufacturing resolution pulling FECD data back into 2026.\n\n## Correlation Notes\n- Direct read-across to the frataxin pool: Larimar (LRMR, nomlabofusp) and PTC Therapeutics (PTCT, vatiquinone) share the patient population; Biogen's approved Skyclarys/omaveloxolone is both the standard of care and the background therapy on which the 2026-05-18 ALT elevations occurred. A competitor readout repricing the pool moves DSGN without a company event.\n- Pre-revenue, single-theme, ~62.5M weighted-average shares (Q2 2026): high beta to small-cap biotech risk appetite (XBI-type flow) and to the rate path, since all value sits in 2027 readouts.\n- Within the rare-disease-gene-therapy theme, DSGN's driver is asset-specific. The theme flipping to saturated would remove the sponsorship that carried the June–July leg, but the Q1-2027 data still decides the platform question on its own.",
  "first_seen": "2026-04-30",
  "last_analyzed": "2026-08-08T15:06:58+00:00",
  "last_synthesized": "2026-08-08",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}